DB:SFYC

Stock Analysis Report

Executive Summary

Synthetic Biologics, Inc., a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States.

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (€9M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months



Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Synthetic Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SFYC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-11.6%

SFYC

1.0%

DE Biotechs

2.0%

DE Market


1 Year Return

-16.0%

SFYC

6.8%

DE Biotechs

15.1%

DE Market

Return vs Industry: SFYC underperformed the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: SFYC underperformed the German Market which returned 15% over the past year.


Shareholder returns

SFYCIndustryMarket
7 Day-11.6%1.0%2.0%
30 Day-2.6%-1.2%1.0%
90 Day30.9%7.4%3.8%
1 Year-16.0%-16.0%7.1%6.8%18.6%15.1%
3 Year-98.2%-98.2%48.3%46.6%16.8%6.6%
5 Year-99.3%-99.3%11.4%9.0%23.7%6.7%

Price Volatility Vs. Market

How volatile is Synthetic Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Synthetic Biologics undervalued compared to its fair value and its price relative to the market?

81.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SFYC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SFYC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SFYC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SFYC is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SFYC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SFYC is overvalued based on its PB Ratio (81.3x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Synthetic Biologics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

87.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SFYC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SFYC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SFYC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SFYC's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if SFYC's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SFYC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Synthetic Biologics performed over the past 5 years?

7.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SFYC is currently unprofitable.

Growing Profit Margin: SFYC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SFYC is unprofitable, but has reduced losses over the past 5 years at a rate of 7.3% per year.

Accelerating Growth: Unable to compare SFYC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SFYC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: SFYC has a negative Return on Equity (-105.89%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Synthetic Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: SFYC's short term assets ($19.8M) exceed its short term liabilities ($5.6M).

Long Term Liabilities: SFYC's short term assets ($19.8M) exceed its long term liabilities ($539.0K).


Debt to Equity History and Analysis

Debt Level: SFYC is debt free.

Reducing Debt: SFYC has not had any debt for past 5 years.


Balance Sheet

Inventory Level: SFYC has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SFYC's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SFYC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SFYC has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -2.8% each year.


Next Steps

Dividend

What is Synthetic Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate SFYC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SFYC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SFYC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SFYC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SFYC's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average board tenure


CEO

Steve Shallcross (58yo)

2.2yrs

Tenure

US$963,411

Compensation

Mr. Steven A. Shallcross, also known as Steve, CPA has been Independent Director of Newgioco Group, Inc. since June 13, 2019. Mr. Shallcross has been the Chief Financial Officer, Treasurer and Secretary at ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD963.41K) is above average for companies of similar size in the German market ($USD412.37K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Steven Shallcross
CEO, CFO2.2yrsUS$963.41k0.30% $24.1k
Scott Tarriff
Independent Director8yrsUS$102.00k0.051% $4.1k
Jeffrey Kraws
Independent Non-Executive Chairman7.8yrsUS$212.00k0.039% $3.2k
Jeffrey Wolf
Independent Director14.1yrsUS$110.00kno data
Curtis Donskey
Member of C Difficile Clinical Advisory Board5.7yrsno datano data
Thomas Louie
Member of C Difficile Clinical Advisory Board5.7yrsno datano data
Ciarán Kelly
Member of C Difficile Clinical Advisory Board5.7yrsno datano data
Mark Wilcox
Chairman of C Difficile Clinical Advisory Board5.7yrsno datano data
Mark Pimentel
Chairman of C-IBS Clinical Advisory Board5.8yrsno datano data
Charles Shoemaker
Member of Infectious Disease Scientific Advisory Board7.3yrsno datano data

5.8yrs

Average Tenure

57yo

Average Age

Experienced Board: SFYC's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 314.1%.


Top Shareholders

Company Information

Synthetic Biologics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Synthetic Biologics, Inc.
  • Ticker: SFYC
  • Exchange: DB
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$8.780m
  • Listing Market Cap: US$8.104m
  • Shares outstanding: 16.81m
  • Website: https://www.syntheticbiologics.com

Number of Employees


Location

  • Synthetic Biologics, Inc.
  • 9605 Medical Center Drive
  • Suite 270
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SFYCDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2006
SYNAMEX (NYSE MKT LLC)YesCommon StockUSUSDNov 2006

Biography

Synthetic Biologics, Inc., a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases, and monoclonal antibody therapies that prevents and treats pertussis. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 21:18
End of Day Share Price2020/02/17 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.